Imaging diagnosis and efficacy monitoring by [⁸⁹Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies.

ABSTRACT: Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy in cancer therapy, their response rate is low. Differences in the prognosis of patients with cancer under anti-PD-L1 treatment are related to the PD-L1 level in tumors. Accurate PD-L1 detection can optimize the accuracy of tumor immunotherapy and avoid ineffective clinical diagnosis and treatments. Methods: We investigated the imaging efficiency and therapy monitoring capacity of [⁸⁹Zr]Zr-DFO-KN035 immunoPET for tumors. We labeled the monodomain anti-PD-L1 antibody KN035 with the radionuclide zirconium-89 and used this tracer for PET imaging. [⁸⁹Zr]Zr-DFO-KN035 uptakes in patients with PD-L1-positive tumors, including primary and metastatic tumors, as well as in norma

SUBMITTER: He H 

PROVIDER: S-EPMC10750192 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature